WO2004000308A1 - 脈管病に関する光物理化学的・診断方法 - Google Patents
脈管病に関する光物理化学的・診断方法 Download PDFInfo
- Publication number
- WO2004000308A1 WO2004000308A1 PCT/JP2003/008016 JP0308016W WO2004000308A1 WO 2004000308 A1 WO2004000308 A1 WO 2004000308A1 JP 0308016 W JP0308016 W JP 0308016W WO 2004000308 A1 WO2004000308 A1 WO 2004000308A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- acid derivative
- acceptable salt
- aspartic acid
- derivative represented
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims description 31
- 208000019553 vascular disease Diseases 0.000 title description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 48
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- 210000005005 sentinel lymph node Anatomy 0.000 claims abstract description 43
- 201000011510 cancer Diseases 0.000 claims abstract description 37
- 206010027476 Metastases Diseases 0.000 claims abstract description 33
- 230000009401 metastasis Effects 0.000 claims abstract description 32
- 206010020649 Hyperkeratosis Diseases 0.000 claims abstract description 28
- 208000001126 Keratosis Diseases 0.000 claims abstract description 28
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 239000002253 acid Substances 0.000 claims abstract description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims description 39
- 150000001509 aspartic acid derivatives Chemical class 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 22
- 159000000000 sodium salts Chemical class 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 239000000032 diagnostic agent Substances 0.000 claims description 11
- 229940039227 diagnostic agent Drugs 0.000 claims description 11
- 238000012790 confirmation Methods 0.000 claims description 7
- 210000001165 lymph node Anatomy 0.000 claims description 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 abstract description 7
- 238000002428 photodynamic therapy Methods 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 229940009098 aspartate Drugs 0.000 abstract 1
- 239000011734 sodium Substances 0.000 description 34
- 238000012360 testing method Methods 0.000 description 31
- 210000003491 skin Anatomy 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 238000009825 accumulation Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 210000004969 inflammatory cell Anatomy 0.000 description 10
- 201000004624 Dermatitis Diseases 0.000 description 9
- 208000009386 Experimental Arthritis Diseases 0.000 description 9
- 201000004681 Psoriasis Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229950010481 5-aminolevulinic acid hydrochloride Drugs 0.000 description 7
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 150000004033 porphyrin derivatives Chemical class 0.000 description 7
- 208000017520 skin disease Diseases 0.000 description 7
- 210000002437 synoviocyte Anatomy 0.000 description 7
- 102000012422 Collagen Type I Human genes 0.000 description 6
- 108010022452 Collagen Type I Proteins 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000008311 hydrophilic ointment Substances 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 238000002073 fluorescence micrograph Methods 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 102000000503 Collagen Type II Human genes 0.000 description 4
- 108010041390 Collagen Type II Proteins 0.000 description 4
- 206010034972 Photosensitivity reaction Diseases 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- -1 retinoids Chemical class 0.000 description 4
- 206010048768 Dermatosis Diseases 0.000 description 3
- 206010023203 Joint destruction Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000005067 joint tissue Anatomy 0.000 description 3
- 229940109328 photofrin Drugs 0.000 description 3
- 239000003504 photosensitizing agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 201000004595 synovitis Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 241000486679 Antitype Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000027932 Collagen disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000009193 PUVA therapy Methods 0.000 description 2
- 241001111421 Pannus Species 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011257 definitive treatment Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 108010078438 epidermal growth inhibitors Proteins 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 201000010453 lymph node cancer Diseases 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000036211 photosensitivity Effects 0.000 description 2
- 208000007578 phototoxic dermatitis Diseases 0.000 description 2
- 231100000018 phototoxicity Toxicity 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 108010029031 Regulatory-Associated Protein of mTOR Proteins 0.000 description 1
- 102100040969 Regulatory-associated protein of mTOR Human genes 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000011250 post-surgery chemotherapy Methods 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000000457 tarsus Anatomy 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
Definitions
- the present invention relates to a photophysicochemical diagnosis and treatment method for vascular disease (PDT: Pho to dynamic Ther) comprising an iminochlorin aspartic acid derivative or a pharmacologically acceptable salt thereof as an active ingredient.
- PDT Pho to dynamic Ther
- apy for the treatment of rheumatism, inflammatory keratosis, sentinel lymph nodes (sentine 1 lymph node: hereinafter referred to as SN), and diagnostic agents for cancer metastasis.
- PDT photophysicochemical diagnosis and treatment
- a certain porphyrin derivative is administered by intravenous injection, etc., and selectively accumulates in cancer (tumor) tissues.
- This treatment is a destructive treatment, and utilizes two properties of the porphyrin derivative: selective accumulation in cancer tissue and photosensitization.
- the present inventors have been diligently studying a porphyrin derivative that can be used for this PDT, and have a single component, which is stable and maintains good accumulation on cancer tissues.
- Various porphyrin derivatives have been provided which have a high rate of excretion from tissues and have reduced phototoxicity.
- titanium sapphire lasers (wavelengths above 670 nm and below 600 nm) and semiconductor lasers (670 nm) can be used as porphyrin derivatives of the following formula (I): (I
- the iminochlorin aspartic acid derivatives represented by the formula (I) and the pharmaceutically acceptable salts thereof particularly the compound which is a sodium salt, namely, ATX-S10 ⁇ Na
- the compound is a compound that has remarkably high accumulation in cancer tissues and selective accumulation in new blood vessels. Therefore, it has been confirmed that it is extremely effective as a therapeutic agent for PDT for the treatment of tumors and age-related macular degeneration, utilizing its excellent properties, and a patent application has already been filed in that regard. (WO98 / 144445).
- Rheumatism is classified as one of the collagen diseases with vascular inflammation as the main symptom, and it is said that it may occur due to abnormalities in immunity. No cure has been established. Currently, rheumatism is treated with drugs such as anti-inflammatory drugs, steroids, and anti-rheumatic drugs, and surgery such as artificial joint replacement, but the probability of complete cure is extremely low. Trauner et al. Studied rheumatoid treatment using PDT, and have already filed a patent (US Pat. No. 5,368,841), which is disclosed therein. Due to the low selective accumulation of the photosensitizer and the long residence time in the body, this photosensitizer has a high risk of phototoxicity.
- inflammatory keratosis causes blood vessels in the dermis of the skin to spread, “Inflammation” caused by the infiltration of all white blood cells into the skin and “keratosis”, the thickening of the skin and thickening of the stratum corneum, occur simultaneously.
- Treatments include anti-inflammatory drugs such as steroids, epidermal growth inhibitors such as retinoids, and ultraviolet radiation therapy (PUVA therapy), but these are not definitive treatments for complete recovery.
- 5-aminolevulinic acid hydrochloride 5-aminolevulinic acid hydrochloride
- 5-ALA is a biosynthetic precursor of protovolphyrin IX, and the compound properties of protoporphyrin IX, that is, low neovascular accumulation, and the longest wavelength absorption edge of 630 nm For this reason, this 5-ALA does not provide a sufficient therapeutic effect.
- the present inventors have focused on the high selective accumulation of the iminochlorin aspartic acid derivative represented by the formula (I) or a pharmacologically acceptable salt thereof in new blood vessels, and We have been conducting a wider range of research on the use of PDT as a therapeutic or diagnostic agent that applies PDT.
- the sodium salt compound, ATX-S10 • Na has excellent accumulation in inflammatory cells caused by new blood vessels in areas other than cancer and ophthalmology, and is a therapeutic agent for skin diseases utilizing PDT.
- sentinel lymph node sentinel 1 lymph node, sometimes referred to as SN hereinafter
- SN sentinel 1 lymph node
- the dye method and the radioisotope method are used to determine the SN.
- the dye method and the radioisotope method are used to determine the SN.
- considerable skill is required to determine the position of the SN using these methods.
- the present inventors focused on the fluorescent properties of the iminochlorin aspartic acid derivative represented by the formula (I) or a pharmacologically acceptable salt thereof, and confirmed the existence site of SN and the cancer metastasis.
- diagnostic agents that can diagnose the presence or absence of cysteine.
- this compound can be used as a diagnostic agent for confirming the presence of an extremely effective SN and for determining the presence or absence of cancer metastasis, and have completed the present invention.
- the present invention relates to a therapeutic agent for rheumatism, a therapeutic agent for inflammatory keratosis, and a treatment for sentinel lymph node (SN) using PDT (Photodynamic acid Therapy). It is an object to confirm the existence site and to provide a diagnostic agent for cancer metastasis. Disclosure of the invention
- Photophysicochemical diagnosis and treatment of vascular disease comprising an iminochlorin aspartic acid derivative or a pharmacologically acceptable salt thereof as an active ingredient
- PDT Photodynamic Therapy
- a basic aspect of the present invention is to evaluate the accumulation of an iminochlorinus-partic acid derivative represented by the above formula (I) or a pharmacologically acceptable salt thereof on neovascular vessels or tumor cells. It is characterized in that PDT therapy is performed using it.
- a first specific embodiment of the present invention relates to the use of the iminochlorin aspartic acid derivative represented by the above formula (I) or a pharmacologically acceptable salt thereof to produce angiogenesis by PDT.
- the drug is a therapeutic agent for rheumatism using PDT containing a pharmacologically acceptable salt thereof as an active ingredient.
- inflammatory keratosis is a disease caused by new blood vessels.
- Inflammatory keratosis is a prominent inflammatory condition among keratosis, that is, a skin disease mainly consisting of flushing and keratinization.
- psoriasis or psoriasis There was psoriasis (par ap soriasis), and its treatment had so far had to rely on drugs that exert strong medicinal properties, such as steroids.
- the iminochlorin aspartic acid derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof is transdermally administered, it efficiently accumulates in inflammatory cells under the epidermis of the skin. After confirming that the compound is a compound of formula (I), irradiation of the accumulated compound of formula (I) with laser irradiation and the use of PDT therapy can very effectively treat this disease.
- the second specific embodiment of the present invention relates to the use of an iminochlorin aspartic acid derivative represented by the above formula (I) or a pharmacologically acceptable salt thereof, and the use of PDT to induce inflammatory cells under the epidermis of the skin.
- a method for inducing dyskeratosis and effectively treating inflammatory keratosis, wherein the iminochlorinus-partic acid derivative represented by the above formula (I) or a pharmacologically active agent thereof used in the method is used. It is a therapeutic drug for inflammatory keratosis (skin disease such as psoriasis) using PDT containing an acceptable salt as an active ingredient.
- sentinel lymph nodes are the lymph nodes that first receive lymph flow from a carcinoma and then undergo metastasis of the tumor. Therefore, tumor lymph node metastasis starts with SN metastasis. Recently, the concept that no metastasis has occurred in other lymph nodes without SN metastasis (sentine 1 nodec on cept: SN concept) has been adopted. S en ti ne l nod enavigati on surgery is being performed.
- the location of the sentinel lymph node can be identified and the presence or absence of cancer metastasis can be determined, the presence or absence of all lymph node cancer metastasis in that symptom can be determined.
- This SN conc ept has already been clinically applied to breast cancer and malignant melanoma by the dye method or radioisotope method described above.
- the present inventors have found that by utilizing the fluorescent properties of the porphyrin derivative, the location of SN and the diagnosis of cancer metastasis can be performed with high sensitivity and safety.
- a third specific embodiment of the present invention relates to an iminoc represented by the formula (I) ⁇
- a method for confirming the location of sentinel lymph nodes (SN) using PDT and diagnosing cancer metastasis using a phosphorus aspartic acid derivative or a pharmacologically acceptable salt thereof as an active ingredient A PDT-based site-confirming site for SN and a diagnostic agent for cancer metastasis, comprising, as an active ingredient, an iminochlorin aspartic acid derivative represented by the above formula (I) or a pharmacologically acceptable salt thereof.
- the iminochlorin aspartic acid derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof is a sodium salt (ATX-S 10 -N a) PDT treatment of rheumatism and remedy for rheumatism, inflammatory keratosis treatment and inflammatory keratosis treatment drug, furthermore, SN site confirmation and cancer metastasis It is a diagnostic method, a site confirming the presence of SN and a diagnostic agent for cancer metastasis.
- FIG. 1 is a graph illustrating the HUVEC survival rate when PDT was performed using ATX—S 10 ⁇ Na of the present invention.
- FIG. 2 is a photograph of macroscopic findings without laser irradiation in a type I collagen arthritis model mouse (control group) after performing 0 tests.
- FIG. 3 is a photograph of macroscopic findings 7 days after laser irradiation in a type II collagen arthritis model mouse (test group) after PDT.
- FIG. 4 is a laser non-irradiation micrograph of a joint tissue section in a type I collagen arthritis model mouse (control group) after performing 0 trials.
- Fig. 5 1 is a photomicrograph of a joint tissue section of a type I collagen arthritis model mouse (test group) after laser irradiation after laser irradiation.
- FIG. 6 is a graph showing the cell killing effect on cultured keratinocytes when PDT was performed using ATX—S 10 ⁇ Na of the present invention.
- AT of the present invention in cultured cells X- S to 10 ⁇ Na was added 50 g / mL, were cultured under the same conditions, then washed with a phosphate buffer, performs, single The one irradiation at 10 JZ cm 2, irradiation after 1, 2, The survival rates of keratinocytes at 3, 6, 12, and 24 hours later were plotted on a graph.
- FIG. 7 is a fluorescence image 3 hours after immersion ointment containing ATX—S 10 ⁇ Na was applied to a dermatitis model mouse.
- (A) is a fluorescence image when applying a submerged ointment containing ATX—S10 ⁇ Na
- (b) is a fluorescence image when applying a submerged ointment that does not contain ATX—S10 ⁇ ⁇ a. It is.
- FIG. 8 is a cross-sectional microscopic photograph of skin tissue in a dermatitis model mouse obtained by applying 1% ATX_S 10Na (10) immersion ointment to the skin of a mouse treated with TPA, and passing 3 hours.
- (A) is a photograph after laser irradiation
- (b) is a photograph without laser irradiation.
- FIG. 9 is a fluorescence image obtained when Photofrin was administered. In the figure, after 5 minutes and 10 minutes from the upper left. 15 minutes and 20 minutes after middle left. Fluorescent images 25 minutes and 30 minutes after the lower left.
- FIG. 10 is a fluorescent image when ATX-S10 ⁇ ⁇ a of the present invention was administered. In the figure, after 5 minutes and 10 minutes from the upper left. 15 minutes and 20 minutes after middle left. Fluorescent images 25 minutes and 30 minutes after the lower left. BEST MODE FOR CARRYING OUT THE INVENTION
- the iminochlorin aspartic acid derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof represented by the formula (I) used as an active ingredient in the present invention is, for example, W098 / 14
- a first specific embodiment provided by the present invention comprises an iminochlorin spargic acid derivative represented by the formula (I) or a pharmacologically acceptable salt thereof, particularly a sodium salt thereof (ATX-S10-Na) as an active ingredient: It is a method of treating rheumatism with PDT, and is a therapeutic agent for rheumatism used for its treatment.
- rheumatoid arthritis which is regarded as an intractable disease, is pathologically proliferative synovitis, formation of subsynovial carcinoma-like tissue (pannus), and cartilage and bone destruction by vannus. It is characterized by clinically causing polyarticular pain, swelling, and dysfunction, and significantly reducing the quality of life of patients over their lifetime. Therefore, the treatment goal for rheumatoid arthritis is to control joint rupture due to proliferative synovitis (pannus). Therefore, as one of the rheumatic treatments, it is necessary to suppress inflammation caused by synovial cells, inhibit angiogenesis, and suppress joint destruction.
- Test 1 invitro test: PD on umbilical cord vascular endothelial cells (HUVEC)
- HUVEC human umbilical cord vascular endothelial cells
- Human umbilical vein endothelial cells (HUVEC), with media, each we 1 1 per 1.
- 0 X 10 - 4 were cultured in eel 1 s / we 1 1, there IL one 1/3 (1 ng / (mL) and TNF-a (10 ng / mL) were added to stimulate the cells to be inflammatory.
- ATX-S10 ⁇ ⁇ a of the present invention was added to 25 ⁇ g / mL and 50 gZmL, respectively, and incubated at 37 ° C for 24 hours.
- the laser irradiation in cultured cells (respectively 0, 1 5, 30, 50 and l OO JZcm 2 irradiated in) and, HU at 24 hours after laser irradiation VEC viability was measured by the MTT Atsey method.
- HUVEC Survival was about 10-20%. Survival rates were similar in both the ATX-S 10'Na supplemented groups at 25 g / mL and 50 ng / mL (Fig. 1).
- a laser-no irradiation group (3 animals per group) was provided.
- the clinical effects were evaluated by clinical joint scores (Arthritis core: Terrato et al., 1995), mice were perfused and fixed, and joint tissues were collected and stained with Safranin 0 The demineralized tissue specimen was evaluated histologically.
- ATX—SIO′Na which is an iminochlorin-aspartic acid derivative of the present invention, is extremely effective for rheumatism treatment by PDT therapy.
- S10 ⁇ Na has high selective accumulation in tumors and inflammatory cells, and its metabolic rate from normal tissues is high, so that the side effects of photosensitivity are significantly reduced.
- it is a compound that has an absorption band in the long wavelength region (670 nm) where the tissue depth is high, treatment by laser irradiation from outside is also possible.
- refractory synovitis which is particularly refractory to rheumatoid arthritis
- intra-articular injection of steroids, arthroscopic synovectomy, or open synovectomy are performed. Is common. Some steroids cannot be repeated intraarticularly, are at risk of infection, and are invasive. In addition, arthroscopic or direct synovectomy requires hospital management, is invasive, and sometimes requires rehabilitation.
- a second embodiment provided by the present invention is an iminochloriner represented by the formula (I): It is a method for treating inflammatory keratosis (dermatosis such as psoriasis) by PDT containing an acid derivative or a pharmacologically acceptable salt thereof, particularly a sodium salt thereof (ATX-S10 ⁇ Na) as an active ingredient. It is used for the treatment of inflammatory keratosis (dermatosis such as psoriasis).
- Inflammatory keratosis is a prominent inflammatory condition among keratosis, ie, a condition mainly consisting of flushing and keratinization.
- psoriasis psoriasis
- parasorisais psoriatic type
- Specific clinical features include psoriatic dermatosis, arthritic psoriasis, and pustular psoriasis.
- the present inventors have found that the iminochlorin aspartic acid derivative represented by the formula (I) provided by the present invention or a pharmacologically acceptable salt thereof, particularly ATX—S 10 ⁇ Na, can be added to inflammatory cells.
- a hydrophilic ointment was prepared using a hydrophilic ointment base of the Japanese Pharmacopoeia and applied to the skin. After application, the skin was washed and a fluorescent image was taken. As a result, it was confirmed that ATX—S10 * Na had accumulated on the skin.
- Test 3 (in Vitro test): Confirmation of cell killing effect on keratinized cultured cells
- Keratinocytes were collected from patients with inflammatory keratosis and cultured at 37 ° C for 24 hours.
- the ATX- S 10 ⁇ Na of the present invention was added 50 GZmL the cultured cells were cultured under the same conditions, then washed with a phosphate buffer, subjected to the laser one irradiation at 10 J / cm 2, after irradiation The keratinocyte viability was observed over time.
- the survival state of the cells on the medium before laser irradiation was defined as 100%, and the cell viability at 1, 2, 3, 6, 12 and 24 hours after irradiation was determined.
- Figure 6 shows the results. After culturing with the addition of ATX-S10 ⁇ Na, the cells were irradiated with laser, and 75% of the keratinocytes had died after 6 hours. Next, using a dermatitis model mouse, ATX The effect of -S10 ⁇ Na was examined by the following test.
- Test 4 (inViVo test): TPA on mouse skin
- hydrophilic ointment base described in the Japanese Pharmacopoeia
- a hydrophilic ointment containing 1% and 10% of ATX-S10 * Na was prepared by a formulation technique widely used in pharmacology.
- test group was irradiated with a laser beam (irradiation: 100 J / cm 2 and no irradiation), and the skin condition was observed histologically.
- FIG. 8 shows a cross-sectional micrograph of the skin tissue with and without laser irradiation. Therefore, the iminochlorin aspartic acid derivative of the present invention represented by the formula (I) or a pharmacologically acceptable salt thereof, particularly ATX—S10Na, efficiently accumulates in inflammatory cells, It was found that laser irradiation with PDT induced necrosis of inflammatory cells, and was effective in treating inflammatory keratosis.
- a third specific embodiment of the present invention is a sentinel lymph node using PDT, comprising an iminochlorin aspartic acid derivative represented by the formula (I) or a pharmacologically acceptable salt thereof as an active ingredient.
- the present inventors have studied the iminochlorin aspartate derivative represented by the formula (I) of the present invention or a pharmacologically acceptable salt thereof, in particular, the fluorescent properties of ATX—S 10 ⁇ Na and tumor cells. Confirmation of the location of the sentinel lymph node and examination of the presence or absence of cancer metastasis were performed according to the following test, utilizing the selective accumulation in the tumor.
- Test 5 Confirmation of the presence of sentinel lymph nodes in mouse foot pods (footpad) and diagnosis of cancer metastasis
- Meth-A cancer cells were implanted in the foot of a mouse using male mice (age of 15 to 18 g) of 6 to 8 weeks of age. After transplantation of the cancer cells, 0.02 mg of ATX-S10 * Na was injected into the tumor as a test sample, and continuously administered for up to 30 minutes after administration, to confirm the location of sentinel lymph nodes in the mouse tarsus and cancer Diagnosis of metastases was imaged using a fluorescence imaging system.
- photofrin was used as a control compound for intravenous administration in the same manner as described above.
- the imaging conditions by the fluorescent image system are as follows.
- Excitation light Light source unit (L7212), lens (E5147-06), fiber (A2873)
- the image image capturing conditions are as follows. S— VHS—>DV—> DV Rap tor (DV Video) Standard setting Image size: 640X480 Frame DV Format
- FIG. 9 is an image obtained when Photofrin (abbreviated as PF) was administered as a control compound
- FIG. 10 shows ATX—S 10 ⁇ Na (abbreviated as S 10) of the present invention. It is an image at the time of administration.
- the site of SN is clarified, and the presence or absence of cancer is determined by biopsy. can do.
- the present invention relates to an iminochlorin aspartic acid derivative represented by the formula (I), in particular, its sodium salt, ATX—S10 ⁇ Na, has high activity against tumor cells or inflammatory cells.
- PDT Photothermic acid therapy
- the present invention provides a therapeutic agent for eumatism, a therapeutic agent for inflammatory keratosis, and a diagnostic agent for confirming the location of sentinel lymph nodes and cancer metastasis.
- the conventional treatment for rheumatoid arthritis requires hospitalization for surgery and is invasive, whereas the treatment agent of the present invention does not require surgery. Furthermore, it inhibits joint destruction by killing synovial cells that directly cause the disease from the outside of the cell, and its medical contribution is enormous.
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2490326A CA2490326C (en) | 2002-06-25 | 2003-06-25 | Photodynamic therapy for vascular diseases |
AU2003243968A AU2003243968B2 (en) | 2002-06-25 | 2003-06-25 | Method of photodynamic diagnosis for vascular diseases |
EP03733569A EP1537867B1 (en) | 2002-06-25 | 2003-06-25 | Method of photodynamic diagnosis for vascular diseases |
US10/518,814 US20050209298A1 (en) | 2002-06-25 | 2003-06-25 | Method of photodynamic diagnosis for vascular diseases |
DK03733569T DK1537867T3 (da) | 2002-06-25 | 2003-06-25 | Fremgangsmåde til fotodynamisk diagnosticering af vaskulære sygdomme |
DE60322918T DE60322918D1 (de) | 2002-06-25 | 2003-06-25 | Verfahren für die photodynamische diagnose von gefässerkrankungen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-185296 | 2002-06-25 | ||
JP2002185296A JP4394334B2 (ja) | 2002-06-25 | 2002-06-25 | 脈管病に関する光物理化学的診断・治療薬 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004000308A1 true WO2004000308A1 (ja) | 2003-12-31 |
Family
ID=29996731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/008016 WO2004000308A1 (ja) | 2002-06-25 | 2003-06-25 | 脈管病に関する光物理化学的・診断方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20050209298A1 (ja) |
EP (2) | EP1847267A3 (ja) |
JP (1) | JP4394334B2 (ja) |
KR (1) | KR100837136B1 (ja) |
AT (1) | ATE404194T1 (ja) |
AU (1) | AU2003243968B2 (ja) |
CA (1) | CA2490326C (ja) |
DE (1) | DE60322918D1 (ja) |
DK (1) | DK1537867T3 (ja) |
ES (1) | ES2312788T3 (ja) |
PT (1) | PT1537867E (ja) |
WO (1) | WO2004000308A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2006085517A1 (ja) * | 2005-02-08 | 2008-06-26 | 株式会社光ケミカル研究所 | クロリン類及びポルフィリン類のpdt用軟膏製剤及び坐剤 |
WO2009065065A1 (en) * | 2007-11-15 | 2009-05-22 | Ceramoptec Industries, Inc. | Pegylated liposomal formulations for photodynamic treatment of inflammatory diseases |
JP5179245B2 (ja) * | 2008-04-30 | 2013-04-10 | 功 阪田 | 皮膚疾患治療剤 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0945454A1 (en) * | 1996-10-01 | 1999-09-29 | Wyeth Lederle Japan LTD. | Iminochlorinaspartic acid derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5368841A (en) * | 1993-02-11 | 1994-11-29 | The General Hospital Corporation | Photodynamic therapy for the destruction of the synovium in the treatment of rheumatoid arthritis and the inflammatory arthritides |
JP3718887B2 (ja) * | 1995-10-30 | 2005-11-24 | 株式会社光ケミカル研究所 | ポルフィリン誘導体とその用途 |
DE19960705A1 (de) * | 1999-12-16 | 2001-06-21 | Laser & Med Tech Gmbh | Verfahren und Vorrichtung zur Herstellung eines autologen Immunisierungsimpfstoffes gegen Krebserkrankungen (Tumorvakzine) |
JP2003012547A (ja) * | 2001-06-27 | 2003-01-15 | Meiji Seika Kaisha Ltd | インスリン依存性糖尿病の診断剤および治療剤 |
-
2002
- 2002-06-25 JP JP2002185296A patent/JP4394334B2/ja not_active Expired - Fee Related
-
2003
- 2003-06-25 DE DE60322918T patent/DE60322918D1/de not_active Expired - Lifetime
- 2003-06-25 US US10/518,814 patent/US20050209298A1/en not_active Abandoned
- 2003-06-25 EP EP07014305A patent/EP1847267A3/en not_active Withdrawn
- 2003-06-25 DK DK03733569T patent/DK1537867T3/da active
- 2003-06-25 KR KR1020047020956A patent/KR100837136B1/ko not_active IP Right Cessation
- 2003-06-25 CA CA2490326A patent/CA2490326C/en not_active Expired - Fee Related
- 2003-06-25 PT PT03733569T patent/PT1537867E/pt unknown
- 2003-06-25 AU AU2003243968A patent/AU2003243968B2/en not_active Ceased
- 2003-06-25 WO PCT/JP2003/008016 patent/WO2004000308A1/ja active IP Right Grant
- 2003-06-25 ES ES03733569T patent/ES2312788T3/es not_active Expired - Lifetime
- 2003-06-25 AT AT03733569T patent/ATE404194T1/de active
- 2003-06-25 EP EP03733569A patent/EP1537867B1/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0945454A1 (en) * | 1996-10-01 | 1999-09-29 | Wyeth Lederle Japan LTD. | Iminochlorinaspartic acid derivatives |
Non-Patent Citations (2)
Title |
---|
LEVY J.G.: "Photodynamic therapy", TRENDS BIOTECHNOL., vol. 13, no. 1, 1995, pages 14 - 18, XP004207115 * |
SUSUMU NAKAJIMA: "Dai ni sedai no photosensitizer ATX-S10Na(II) no koshuyo koka", IGAKU NO AYUMI, vol. 180, no. 10, 1997, pages 689 - 690, XP002116545 * |
Also Published As
Publication number | Publication date |
---|---|
EP1537867B1 (en) | 2008-08-13 |
KR100837136B1 (ko) | 2008-06-11 |
ES2312788T3 (es) | 2009-03-01 |
EP1847267A2 (en) | 2007-10-24 |
EP1537867A4 (en) | 2006-10-11 |
US20050209298A1 (en) | 2005-09-22 |
DK1537867T3 (da) | 2008-11-10 |
AU2003243968B2 (en) | 2008-01-31 |
CA2490326C (en) | 2010-09-07 |
JP4394334B2 (ja) | 2010-01-06 |
PT1537867E (pt) | 2008-10-09 |
EP1537867A1 (en) | 2005-06-08 |
EP1847267A3 (en) | 2010-07-07 |
DE60322918D1 (de) | 2008-09-25 |
AU2003243968A1 (en) | 2004-01-06 |
KR20050016619A (ko) | 2005-02-21 |
ATE404194T1 (de) | 2008-08-15 |
JP2004026717A (ja) | 2004-01-29 |
CA2490326A1 (en) | 2003-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Loh et al. | Photodynamic therapy of the normal rat stomach: a comparative study between di-sulphonated aluminium phthalocyanine and 5-aminolaevulinic acid | |
JP3154742B2 (ja) | 哺乳類の動脈硬化症治療剤 | |
JP2010163445A (ja) | 組織病変部の診断または治療のための溶液 | |
JPH06305961A (ja) | 哺乳類の関節炎の診断剤および/または治療剤 | |
Li et al. | Photodynamic therapy in the treatment of malignant tumours: an analysis of 540 cases | |
KR20140110757A (ko) | 질병을 치료하는 바이러스 불활성화 약물의 제조에서 광감각제의 용도 | |
WO1998014453A1 (fr) | Derives d'acide iminochlorinaspartique | |
RU2376044C1 (ru) | Способ определения оптимальных режимов флуоресцентной диагностики и фотодинамической терапии | |
Zhang et al. | 5-Aminolevulinic Acid Photodynamic Therapy combined with CO2 Laser Therapy in treatment of laryngeal papilloma: Case report | |
WO2004000308A1 (ja) | 脈管病に関する光物理化学的・診断方法 | |
US11654195B2 (en) | Eco-friendly smart photosensitizer and photo-stem cell therapy product comprising same | |
US10493169B2 (en) | Use of charge-balanced imaging agents for determining renal function | |
WO2001040234A1 (fr) | Compose porphyrine | |
RU2228775C1 (ru) | Способ фотодинамического лечения острого и хронического гнойного гайморита | |
US20030157026A1 (en) | Photodynamic diagnosis and therapy for insulin-dependent diabetes mellitus | |
RU2797433C1 (ru) | Способ интраоперационной фотодинамической терапии в комбинированном лечении первичного местно-распространенного рака языка | |
Grönlund-Pakkanen et al. | The importance of fluorescence distribution and kinetics of ALA-induced PpIX in the bladder in photodynamic therapy | |
RU2815182C1 (ru) | Способ проведения адаптивной лимфотропной фотодинамической терапии | |
CN117159707A (zh) | 一种近红外荧光探针wl-808在制备用于靶向治疗异位骨化的药物中的应用 | |
RU2612821C1 (ru) | Способ лечения крауроза вульвы, связанного с наличием у пациентки вируса папилломы человека | |
RU2204426C1 (ru) | Способ фотодинамической диагностики и терапии больных первично-множественным раком кожи | |
RU2243756C1 (ru) | Способ профилактики и лечения метастазов после хирургического удаления внутриглазных новообразований | |
WO2006085517A1 (ja) | クロリン類及びポルフィリン類のpdt用軟膏製剤及び坐剤 | |
EP1413313A1 (en) | DIAGNOSIS AND TREATMENT OF INSULIN&minus;DEPENDENT DIABETES MELLITUS AND INSULITIS | |
RU2445027C1 (ru) | Способ лечения папилломатоза гортани |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003243968 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2490326 Country of ref document: CA Ref document number: 10518814 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047020956 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003733569 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047020956 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003733569 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003733569 Country of ref document: EP |